International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases

Lewin, Sara; Lees, Charlie W; Regueiro, Miguel; Hart, Ailsa; M, Uma

doi:10.1093/ecco-jcc/jjaa140

Cited by 24 publications

(28 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Today it is COVID-19, but in the future, it could be some other virus, especially as we are now more than ever aware of our susceptibility to a viral pandemic. IOIBD/ECCO issued a summary of the best strategies for IBD management via telemedicine, carefully covering every aspect of the patient-physician relationship[ 101 ]. Another very important aspect of telemedicine is its inexpensiveness.…”

Section: The Impact Of the Covid-19 Pandemic On Ibd Management: Present And Future Perspectivesmentioning

confidence: 99%

Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence

Kumrić

Kurir

Martinović

et al. 2021

WJG

View full text Add to dashboard Cite

Since the initial coronavirus disease 2019 (COVID-19) outbreak in China in December 2019, the infection has now become the biggest medical issue of modern medicine. Two major contributors that amplified the impact of the disease and subsequently increased the burden on health care systems were high mortality among patients with multiple co-morbidities and overcapacity of intensive care units. Within the gastroenterology-related community, particular concern was raised with respect to patients with inflammatory bowel disease (IBD), as those patients are prone to opportunistic infections mainly owing to their immunosuppressive-based therapies. Hence, we sought to summarize current knowledge regarding COVID-19 infection in patients with IBD. Overall, it seems that IBD is not a comorbidity that poses an increased risk for COVID-19 acquisition, except in patients treated with 5-aminosalicylates. Furthermore, outcomes of the infected patients are largely dependent on therapeutic modality by which they are treated, as some worsen the clinical course of COVID-19 infection, whereas others seem to dampen the detrimental effects of COVID-19. Finally, we discussed the present and the future impact of COVID-19 pandemic and concomitantly increased health care burden on IBD-management.

show abstract

Section: The Impact Of the Covid-19 Pandemic On Ibd Management: Present And Future Perspectivesmentioning

confidence: 99%

Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence

Kumrić

Kurir

Martinović

et al. 2021

WJG

View full text Add to dashboard Cite

show abstract

“…The rapid and widespread innovation of health care delivery from the pre-pandemic era was not without precedent; ( 33 ) Crohn’s and Colitis Canada had already developed the Promoting Access and Care through Centers of Excellence (PACE) Telemedicine Program in Ontario ( 34 ). Moreover, during the pandemic, studies of people with IBD and health care providers identified increased satisfaction, improved outcomes, and greater efficiency with the health care innovations (e.g., Telemedicine) such that the future of IBD care will most likely comprise hybrid models of in-person and virtual health care delivery ( 35 ).…”

Section: Methodsmentioning

confidence: 99%

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary

Kuenzig

Windsor

Barrett

et al. 2021

Journal of the Canadian Association of Gastroenterology

View full text Add to dashboard Cite

Persons with inflammatory bowel disease (IBD) make up more than 0.75% of the Canadian population in 2021. Early in the COVID-19 pandemic, individuals with IBD, particularly those on immunosuppressive therapies, were concerned that their health status may place them at higher risk of contracting COVID-19 or experiencing more severe disease course if infected with SARS-CoV-2. In response, Crohn’s and Colitis Canada developed the COVID-19 and IBD Taskforce in March 2020 to rapidly synthesize the evolving knowledge of COVID-19 as relevant to Canadians with IBD. The Taskforce communicated expert information directly to the Canadian IBD community through online tools and a webinar series. In order to understand the full impact of COVID-19 on the IBD community, Crohn’s and Colitis Canada commissioned a policy report that was informed through a systematic literature review and synthesized across working groups along the following domains: Epidemiology, Children and Expectant Mothers with IBD, Seniors with IBD, Mental Health, Risk Factors and Medications, Vaccines, and Healthcare Delivery during the Pandemic and the Future Model of IBD Care. This report from Canadian physicians, researchers, and IBD community representatives highlights the physical, mental, and health systems impact of COVID-19 on the entire spectrum of the IBD community, including children, adolescents, adults, seniors, and pregnant people with IBD. This executive summary provides an overview of the crucial information from each of the chapters of the policy report, supplemented with additional information made available through Crohn’s and Colitis Canada’s webinar-based knowledge translation platform.

show abstract

“…They question our "pre-pandemic" paradigms around aspects of health care delivery. 8,9 The near universal adoption of telemedicine and components needed for its delivery have been available even in the pre-pandemic era severe COVID-19 outcomes. 10,11 Also, that clinically active IBD at the onset of viral infection is a strong independent risk factor for | 265 INVITED EDITORIAL serious infection, making it imperative for clinicians to factor IBD severity and activity into individual treatment choices in the light of evolving knowledge.…”

Section: N V I T E D E D I T O R I a Lmentioning

confidence: 99%

“…Even as a growing body of literature supports these initiatives, 3,4,6,7 their findings early in the pandemic need to be taken in context. They question our “pre‐pandemic” paradigms around aspects of health care delivery 8,9 . The near universal adoption of telemedicine and components needed for its delivery have been available even in the pre‐pandemic era but have been underutilised by healthcare professionals, particularly by doctors for out‐patient services and communication between professionals.…”

mentioning

confidence: 99%

Inflammatory bowel disease service redesign during the COVID‐19 pandemic: Living, learning and delivering care amidst angst and uncertainty

Limdi

2020

GastroHep

View full text Add to dashboard Cite

International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases

Cited by 24 publications

References 14 publications

Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence

Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence

Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary

Inflammatory bowel disease service redesign during the COVID‐19 pandemic: Living, learning and delivering care amidst angst and uncertainty

Contact Info

Product

Resources

About